Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
An article from
News roundup
Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, a prolific university advanced a new ebola vaccine.
Published July 13, 2026
Getty Images
Why Is Agenus Stock Gaining Monday? - Agenus (NASDAQ:AGEN)
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
Why Is Agenus Stock Falling on Tuesday? - Agenus (NASDAQ:AGEN)
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO…
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two…
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO…
Agenus Inc. (Nasdaq: AGEN) , leader nell’innovazione in campo immuno-oncologico, ha annunciato oggi i dati di riferimento…
